KDR and non-small cell lung carcinoma: Our results demonstrated a shorter median survival time after prognosis in late-stage NSCLC patients with high levels of VEGFR-2 expression (14 months) compared to late-stage NSCLC patients with low VEGFR-2 expression (21 months) (p < 0.05) (Figure 8B).